Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT06311214
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
500 Enrollment(s)
27 Study location(s)
INTERVENTIONAL (PHASE2)
Advanced Malignant Solid Neoplasm


Metastatic Malignant Solid Neoplasm
ACTIVE_NOT_RECRUITING
NCT04704661
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
51 Enrollment(s)
23 Study location(s)
INTERVENTIONAL (PHASE1)
Advanced Breast Carcinoma


Advanced Colon Carcinoma


Advanced Colorectal Carcinoma


Advanced Endometrial Carcinoma


Advanced Gastric Carcinoma


Advanced Gastroesophageal Junction Adenocarcinoma


Advanced Malignant Solid Neoplasm


Advanced Salivary Gland Carcinoma


Anatomic Stage III Breast Cancer AJCC v8


Anatomic Stage IV Breast Cancer AJCC v8


Clinical Stage III Gastric Cancer AJCC v8


Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8


Clinical Stage IV Gastric Cancer AJCC v8


Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8


HER2-Positive Breast Carcinoma


Malignant Hepatobiliary Neoplasm


Metastatic Breast Carcinoma


Metastatic Colon Carcinoma


Metastatic Colorectal Carcinoma


Metastatic Endometrial Carcinoma


Metastatic Gastric Carcinoma


Metastatic Gastroesophageal Junction Adenocarcinoma


Metastatic Malignant Solid Neoplasm


Metastatic Salivary Gland Carcinoma


Stage III Colon Cancer AJCC v8


Stage III Colorectal Cancer AJCC v8


Stage III Major Salivary Gland Cancer AJCC v8


Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8


Stage IV Colon Cancer AJCC v8


Stage IV Colorectal Cancer AJCC v8


Stage IV Major Salivary Gland Cancer AJCC v8


Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8


Unresectable Breast Carcinoma


Unresectable Colon Carcinoma


Unresectable Colorectal Carcinoma


Unresectable Endometrial Carcinoma


Unresectable Gastric Carcinoma


Unresectable Gastroesophageal Junction Adenocarcinoma


Unresectable Malignant Solid Neoplasm


Unresectable Salivary Gland Carcinoma
RECRUITING
NCT07647016
Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study
53 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer
RECRUITING
NCT05950945
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
250 Enrollment(s)
88 Study location(s)
INTERVENTIONAL (PHASE3)
Breast Cancer
RECRUITING
NCT04047641
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
80 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Acute Myeloid Leukemia


Blasts 20 Percent or More of Bone Marrow Nucleated Cells


High Risk Myelodysplastic Syndrome


Recurrent Acute Biphenotypic Leukemia


Recurrent Acute Myeloid Leukemia


Recurrent High Risk Myelodysplastic Syndrome


Refractory Acute Myeloid Leukemia


Refractory High Risk Myelodysplastic Syndrome
NOT_YET_RECRUITING
NCT07619521
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma
31 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Advanced Pancreatic Ductal Adenocarcinoma


Metastatic Pancreatic Ductal Adenocarcinoma


Stage III Pancreatic Cancer AJCC v8


Stage IV Pancreatic Cancer AJCC v8


Unresectable Pancreatic Ductal Adenocarcinoma
NOT_YET_RECRUITING
NCT07318389
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
100 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (EARLY_PHASE1)
Dynamic Tumor Resistance


Metastatic Colorectal Cancer
RECRUITING
NCT07198724
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
65 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Metastatic Breast Cancer


HER2 Low Breast Carcinoma


HER2-negative Breast Cancer


Breast Cancer


Breast Cancer Female